An international research team, funded in part by the Foundation Fighting Blindness, has used gene therapy to reactivate retinal cells that were previously unresponsive to light. The treatment was delivered to cones, the retinal cells that provide central and daytime vision. Investigators evaluated the gene therapy in two mouse models of retinal degenerative disease, as well as cultures of human retinal tissue. Using a variety of tests, the researchers demonstrated that the treated cells restored functional vision, and that the restoration of vision persisted over a long period of time.
In a study funded by the Foundation Fighting Blindness, researchers have found that a gene known as LIPC appears to be associated with a decreased risk of developing age-related macular degeneration (AMD), the leading cause of blindness in Americans 55 years-of-age and older. The finding gives researchers more clues about AMD, a complex disease caused by multiple genetic and environmental factors, and potentially new targets for vision-saving preventions and treatments.
Researchers have discovered several risk factors that appear to be associated with macular degeneration.
Username
Password
Select a state from the dropdown below to view local chapters.
Register here to receive free information about your eye condition and research efforts to find treatments and cures.